Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322.

O'Dwyer K, Hackel M, Hightower S, Hoban D, Bouchillon S, Qin D, Aubart K, Zalacain M, Butler D.

Antimicrob Agents Chemother. 2013 May;57(5):2333-42. doi: 10.1128/AAC.02566-12. Epub 2013 Mar 11.

2.

Pharmacokinetics/Pharmacodynamics of Peptide Deformylase Inhibitor GSK1322322 against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Rodent Models of Infection.

Hoover J, Lewandowski T, Straub RJ, Novick SJ, DeMarsh P, Aubart K, Rittenhouse S, Zalacain M.

Antimicrob Agents Chemother. 2015 Oct 19;60(1):180-9. doi: 10.1128/AAC.01842-15.

3.

Frequency of Spontaneous Resistance to Peptide Deformylase Inhibitor GSK1322322 in Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus pneumoniae.

Min S, Ingraham K, Huang J, McCloskey L, Rilling S, Windau A, Pizzollo J, Butler D, Aubart K, Miller LA, Zalacain M, Holmes DJ, O'Dwyer K.

Antimicrob Agents Chemother. 2015 Aug;59(8):4644-52. doi: 10.1128/AAC.00484-15. Epub 2015 May 26.

4.

In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698.

Lofland D, Difuntorum S, Waller A, Clements JM, Weaver MK, Karlowsky JA, Johnson K.

J Antimicrob Chemother. 2004 Apr;53(4):664-8. Epub 2004 Feb 18.

PMID:
14973152
5.

Potent sub-MIC effect of GSK1322322 and other peptide deformylase inhibitors on in vitro growth of Staphylococcus aureus.

Butler D, Chen D, O'Dwyer K, Lewandowski T, Aubart K, Zalacain M.

Antimicrob Agents Chemother. 2014;58(1):290-6. doi: 10.1128/AAC.01292-13. Epub 2013 Oct 28.

7.

Determination of disk diffusion and MIC quality control ranges for GSK1322322, a novel peptide deformylase inhibitor.

Ross JE, Scangarella-Oman NE, Miller LA, Sader HS, Jones RN.

J Clin Microbiol. 2011 Nov;49(11):3928-30. doi: 10.1128/JCM.01213-11. Epub 2011 Sep 14.

8.
10.

Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010.

Paukner S, Sader HS, Ivezic-Schoenfeld Z, Jones RN.

Antimicrob Agents Chemother. 2013 Sep;57(9):4489-95. doi: 10.1128/AAC.00358-13. Epub 2013 Jul 8.

11.
12.

Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents.

Blondeau JM, Vaughan D, Laskowski R, Borsos S; Canadian Antimicrobial Study Group.

Int J Antimicrob Agents. 2001 Jun;17(6):457-64.

PMID:
11397615
13.

In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.

Yang Q, Xu Y, Chen M, Wang H, Sun H, Hu Y, Zhang R, Duan Q, Zhuo C, Cao B, Liu Y, Yu Y, Sun Z, Chu Y.

Diagn Microbiol Infect Dis. 2012 Jun;73(2):187-91. doi: 10.1016/j.diagmicrobio.2012.03.005. Epub 2012 Apr 21.

PMID:
22521692
14.

In vitro activity of cefdinir against respiratory pathogens isolated in Sicily with reference to beta-lactamase production.

Blandino G, Aleo G, Caccamo F, Nicolosi VM, Siracusa V, Speciale A.

J Chemother. 1996 Jun;8(3):193-9.

PMID:
8808715
15.

Activity of gatifloxacin compared to those of seven agents against bacteria recovered from outpatients with respiratory tract infection.

Smayevsky J, Lopez H, Di Chiara M, Scarano S, Lanza A, Vilches V, Stepanik D, Bantar C, Sucari A.

Diagn Microbiol Infect Dis. 2000 Aug;37(4):261-4.

PMID:
10974577
17.

Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria.

Clark C, McGhee P, Appelbaum PC, Kosowska-Shick K.

Antimicrob Agents Chemother. 2011 May;55(5):2344-51. doi: 10.1128/AAC.01602-10. Epub 2011 Feb 22.

18.

In vitro antibacterial activity of modithromycin, a novel 6,11-bridged bicyclolide, against respiratory pathogens, including macrolide-resistant Gram-positive cocci.

Sato T, Tateda K, Kimura S, Iwata M, Ishii Y, Yamaguchi K.

Antimicrob Agents Chemother. 2011 Apr;55(4):1588-93. doi: 10.1128/AAC.01469-10. Epub 2011 Jan 10.

19.

Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000).

Mendes C, Marin ME, Quiñones F, Sifuentes-Osornio J, Siller CC, Castanheira M, Zoccoli CM, López H, Súcari A, Rossi F, Angulo GB, Segura AJ, Starling C, Mimica I, Felmingham D.

Braz J Infect Dis. 2003 Feb;7(1):44-61.

20.

[Antimicrobial activities of macrolides against recent clinical isolates, and analysis of resistant mechanisms].

Okubo T, Iyobe S, Fujiki Y, Sagai H.

Jpn J Antibiot. 2003 Jun;56(3):163-70. Japanese.

PMID:
12942787

Supplemental Content

Support Center